{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:33:49Z","timestamp":1777725229901,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jtocrr.2023.100563","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T21:38:24Z","timestamp":1692394704000},"page":"100563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"4","author":[{"given":"Monia","family":"Sisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Riefolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"D\u2019Errico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2023.100563_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2023.100563_bib2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100563_bib3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100563_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cllc.2022.01.003","article-title":"Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: a clinical review","volume":"23","author":"Cortot","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2023.100563_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib6","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1016\/j.cgh.2020.04.034","article-title":"Agreement between 2-dimensional shear wave and transient elastography values for diagnosis of advanced chronic liver disease","volume":"18","author":"Cassinotto","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib7","article-title":"Pharmacotherapies for drug-induced liver injury: A current literature review","volume":"12","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"suppl 4","key":"10.1016\/j.jtocrr.2023.100563_bib8","doi-asserted-by":"crossref","first-page":"S830","DOI":"10.1016\/j.annonc.2020.08.1599","article-title":"Capmatinib in patients with METex14-mutated advanced nonsmall cell lung cancer who received prior immunotherapy: the phase II GEOMETRY mono-1 study","volume":"31","author":"Vansteenkiste","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2023.100563_bib10","first-page":"1222","article-title":"European Association for the Study of the Liver. Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative. EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jtocrr.2023.100563_bib14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jtho.2022.02.004","article-title":"Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001","volume":"17","author":"McCoach","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2023.100563_bib18","first-page":"S186","article-title":"Time from immune checkpoint inhibitor to sotorasib correlates with risk of hepatotoxicity in non-small cell lung cancer","volume":"17","author":"Rakshit","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib19","author":"Chour"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2023.100563_bib20","doi-asserted-by":"crossref","first-page":"S1007","DOI":"10.1016\/j.annonc.2022.07.1120","article-title":"Efficacy and safety of capmatinib plus spartalizumab in treatment-na\u00efve patients with advanced NSCLC harboring MET exon 14 skipping mutation","volume":"33","author":"Wolf","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2023.100563_bib21","author":"Valencia Soto"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:38:58Z","timestamp":1762987138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364323001066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2666364323001066"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100563","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100563"}}